Sinphar Pharmaceutical Co Ltd (1734) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Sinphar Pharmaceutical Co Ltd TWD 28.46, price TWD 32.10, upside -11.3%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sinphar Pharmaceutical Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 26.50 TWD – 42.03 TWD · fair‑value band 18.85 TWD – 39.33 TWD · the 32.10 TWD price screens above the 28.46 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Sinphar Pharmaceutical Co in your weekly email
Every Wednesday you see whether Sinphar Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others.
Show more
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and other products; and healthy food under the Sinphar, DailyCare, Migus, YouBest, and SynCoreBio brands. It also provides moisturizer repair essence, anti aging cream, renewable oi, and UV defence cream under the DYNASKIN brand; serum, revitalizing cream, hygiene, sunblock, sunscreen, and lightening tables under the Yestuner brand; and shower gel and hair shampoo. In addition, the company is involved in the provision of testing and development, as well as product design and manufacturing services. The company was incorporated in 1977 and is based in Yilan City, Taiwan.
Stock analysis
Sinphar Pharmaceutical Co Ltd (1734) currently trades at 32.10 TWD, while our model-based Fair Value estimate is 28.46 TWD, implying the stock looks roughly 12.8% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 34.64 TWD per share, and 9 of the 25 models we run sit above the 32.10 TWD price.
Bear case: the Dividend Discount group reads lowest at 9.12 TWD, and 16 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: 18.85 TWD (bear) to 39.33 TWD (bull), the price of 32.10 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Sinphar Pharmaceutical Co Ltd reported revenue of 3.4B TWD in FY2025 versus 2.4B TWD in FY2021, a compound +8.5%/yr. Reported net income was 366M TWD in FY2025.
Key figures
Market cap 5.9B TWD (≈ $186M) · P/E ratio 16.7 · P/S ratio 1.81 · EPS (TTM) 1.92 TWD · Dividend yield 3.1% · Net margin 10.8% · Return on equity 8.4% · Return on assets (EBIT) 3.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 7% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −11%, 1734 screens richer than that median.
Fair Value models
Bear 18.85 TWDFair Value 28.46 TWDBull 39.33 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.6730 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Start year 2020 (pandemic). Over 10 years: +4.4% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+94.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+91.5%
Dividend (yield on the price)3.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.92% vs 35%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 12%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +9.4% a year for the price.
Compare Sinphar Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside−11% · Above median
Profitability
Return on equity (TTM)8% · Top 25%
Return on assets4% · Top 25%
Net margin (TTM)10% · Above median
Operating margin (TTM)11% · Above median
Growth and dividend
Revenue growth3% · Above median
Dividend yield (TTM)3.1% · Top 25%
Balance sheet
Debt / equity0.37× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sinphar Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1734
Frequently asked questions
Is Sinphar Pharmaceutical Co Ltd (1734) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 28.46 TWD versus a price of 32.10 TWD, about −11% upside (overvalued).
What is the fair value of 1734?
Our model-based fair value for Sinphar Pharmaceutical Co Ltd is 28.46 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 32.10 TWD.
What is the quality score of 1734?
Sinphar Pharmaceutical Co Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sinphar Pharmaceutical Co Ltd (1734)?
Our model-based price target is the fair value of 28.46 TWD (as of Sep 24, 2026) from 25 valuation models. Cautious scenario 18.85 TWD, optimistic scenario 39.33 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Sinphar Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at 28.46 TWD, about −11% upside versus a price of 32.10 TWD (overvalued). Cautious scenario 18.85 TWD, optimistic scenario 39.33 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Sinphar Pharmaceutical Co Ltd (1734)?
Sinphar Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 3.4B TWD (latest available figure, as of Sep 24, 2026).
Does Sinphar Pharmaceutical Co Ltd pay a dividend?
Sinphar Pharmaceutical Co Ltd currently shows a dividend yield of about 3.12% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Sinphar Pharmaceutical Co Ltd (1734)?
For today's price to be fair in a discounted-cash-flow model, Sinphar Pharmaceutical Co Ltd would have to grow free cash flow by +11.1 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 1734 use?
Our models discount Sinphar Pharmaceutical Co Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.11, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sinphar Pharmaceutical Co Ltd that is +11.1 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Sinphar Pharmaceutical Co Ltd (1734) delivered so far?
Over the past 5 years revenue at Sinphar Pharmaceutical Co Ltd grew +7.1 % a year. The price currently implies +11.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sinphar Pharmaceutical Co Ltd (1734) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Sinphar Pharmaceutical Co Ltd (+11.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sinphar Pharmaceutical Co Ltd (1734)?
The free-cash-flow yield on the price is 6.48 %: that much free cash flow Sinphar Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sinphar Pharmaceutical Co Ltd (1734)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sinphar Pharmaceutical Co Ltd it is 28.46 TWD per share (as of Sep 24, 2026), against a price of 32.10 TWD. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Sinphar Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1734 trades above its calculated fair value: price 32.10 TWD, fair value 28.46 TWD, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1734?
No. The price is what the market pays today (32.10 TWD); the fair value is what the company's own numbers justify (28.46 TWD). For Sinphar Pharmaceutical Co Ltd the two are 3.64 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Sinphar Pharmaceutical Co Ltd worth?
The market values Sinphar Pharmaceutical Co Ltd at about 5.9B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 32.10 TWD; our models calculate a fair value of 28.46 TWD per share.
What do the bullish and bearish scenarios say about 1734?
Our models span a range for Sinphar Pharmaceutical Co Ltd: cautious scenario 18.85 TWD, base 28.46 TWD, optimistic 39.33 TWD per share (as of Sep 24, 2026, price 32.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1734?
Sinphar Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 16.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 28.46 TWD is built from several models across several years. Other multiples: PEG 1.9, P/B 1.7, P/S 1.7, EV/EBITDA 9.9.
What is the PEG ratio of 1734?
The PEG ratio of Sinphar Pharmaceutical Co Ltd is 1.86 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sinphar Pharmaceutical Co Ltd (1734)?
Balance-sheet figures for Sinphar Pharmaceutical Co Ltd (as of Sep 24, 2026): return on equity 8.4%, debt of 0.37 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 1734 from its 52-week high?
Sinphar Pharmaceutical Co Ltd trades at 32.10 TWD, about 5% below its 52-week high of 33.80 TWD and 7% above the low of 30.05 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 28.46 TWD is for.
Which stocks are comparable to Sinphar Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sinphar Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 32.10 TWD, calculated fair value 28.46 TWD (−11%), Quality Score 66/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1734 calculated?
We run Sinphar Pharmaceutical Co Ltd through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 28.46 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Sinphar Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sinphar Pharmaceutical Co Ltd (1734)?
The closing price on Sep 24, 2026 was 32.10 TWD. Our model-based fair value is 28.46 TWD, about −11% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sinphar Pharmaceutical Co Ltd right now?
A fairly wide model range (18.85 TWD to 39.33 TWD) leaves room in how you read the outcome. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Sinphar Pharmaceutical Co Ltd
How large is the market capitalisation of Sinphar Pharmaceutical Co Ltd (1734)?
The market capitalisation of Sinphar Pharmaceutical Co Ltd is 5.9B TWD (≈ $186M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sinphar Pharmaceutical Co Ltd (1734)?
The price-to-sales ratio of Sinphar Pharmaceutical Co Ltd is 1.81 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sinphar Pharmaceutical Co Ltd (1734)?
Earnings per share at Sinphar Pharmaceutical Co Ltd are 1.92 TWD (price ÷ EPS = P/E 16.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sinphar Pharmaceutical Co Ltd (1734)?
The dividend yield of Sinphar Pharmaceutical Co Ltd is 3.1% (payout 52.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sinphar Pharmaceutical Co Ltd (1734)?
The net margin of Sinphar Pharmaceutical Co Ltd is 10.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sinphar Pharmaceutical Co Ltd (1734)?
The return on equity (ROE) of Sinphar Pharmaceutical Co Ltd is 8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sinphar Pharmaceutical Co Ltd (1734)?
On an EBIT basis the return on assets of Sinphar Pharmaceutical Co Ltd is 3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sinphar Pharmaceutical Co Ltd (1734)?
The operating margin of Sinphar Pharmaceutical Co Ltd is 11.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sinphar Pharmaceutical Co Ltd (1734)?
Revenue at Sinphar Pharmaceutical Co Ltd is growing +2.6% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sinphar Pharmaceutical Co Ltd (1734)?
Earnings per share at Sinphar Pharmaceutical Co Ltd are growing −34.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sinphar Pharmaceutical Co Ltd (1734) carry?
The net debt of Sinphar Pharmaceutical Co Ltd is 646M TWD (fiscal year 2025, ≈ 1.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sinphar Pharmaceutical Co Ltd in the live analysis
One click puts Sinphar Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
